A Novel Tyrosine Kinase Inhibitor Poised to Transform Advanced Lung Cancer Care Boehringer Ingelheim | Ridgefield, Conn., and Ingelheim, Germany…
Browsing: #CancerTreatment
Transforming MIBC Treatment: Insights from the NIAGARA TrialPosted on February 16, 2025The landscape of treating muscle-invasive bladder cancer (MIBC) has…
In the evolving landscape of cancer careIn the evolving landscape of cancer care, the use of circulating tumor DNA (ctDNA),…
In a recent interview with Dr. Ignacio Garrido-Laguna from the University of Utah Health, we gained fascinating insights into the…
On January 16, 2025, a significant advancement in cancer treatment was announced. The FDA approved a new therapeutic option for…
In an enlightening discussion at the latest medical symposium, Dr. Jonathan Nowak, MD from Brigham and Women’s Hospital, shared critical…
We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.
“So basically, we looked at two factors, the one saying the long term remission of heart positive metastatic breast cancer…
EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer TreatmentThe results of the Phase 3 EMBER-3 trial were unveiled at the…
On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
IntroductionOn August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (TECELRA) for treating adults with unresectable or metastatic…
On August 1, 2024, the U.S. Food and Drug Administration (FDA) approved an expanded indication for dostarlimab-gxly (Jemperli), in combination…
IntroductionASCO 2024 Head & Neck Cancer developments brought forth several groundbreaking studies in the field of head and neck cancer,…
Presented by Dr. Hedyeh Ebrahimi, City of HopeOverview: At the ASCO 2024 conference, Dr. Hedyeh Ebrahimi of City of Hope…